OraSure Technologies (OSUR) Stock Analysis & AI Equity Report

Medical - Instruments & Supplies USD Explore free reports

OraSure Technologies (OSUR) overview

OraSure Technologies (OSUR) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 115m and operating profit of USD -72.0m; the year-end share price was 2.42 USD and market capitalisation was USD 170m. OraSure Technologies is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get OraSure Technologies's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 341mFY 2025
Share price2.42 USDFY 2025 year end
RevenueUSD 115mFY 2025
Operating profitUSD -72.0mFY 2025
Net earningsUSD -68.7mFY 2025
Market capitalisationUSD 170mFY 2025 year end

About OraSure Technologies

OraSure Technologies develops, manufactures, markets, sells, and distributes diagnostic products and sample management solutions. Its products include rapid tests for HIV, hepatitis C, syphilis, sickle cell disease, and COVID-19, as well as specimen collection devices. Customers include laboratories, hospitals, clinics, public health organizations, distributors, government agencies, researchers, and pharmaceutical and biotechnology companies.

Generate the OraSure Technologies report

OraSure Technologies is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for OraSure Technologies and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on OraSure Technologies

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.